The Prognosis of Lipid Reprogramming with Rosuvastatin, in Castrated Egyptian Prostate Cancer Patients

The Prognosis of Lipid Reprogramming with the HMG-CoA Reductase Inhibitor, Rosuvastatin, in Castrated Egyptian Prostate Cancer Patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202102664354163

Enrollment

Registered

2021-02-24

Start date

2019-01-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Interventions

Rosuvastatin

surgical castration

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Naïve newly diagnosed with metastatic prostate cancer Age = 50 years No psychological or geographical barriers for regular follow up of the patients.

Exclusion criteria

Exclusion criteria: Age < 50 years psychological or geographical barriers for regular follow up of the patients.

Design outcomes

Primary

Measure	Time frame
assess the effect of rosuvastatin addition to surgical castration in metastatic prostate cancer patients by measuring the lipid profile parameters, lipid metabolism related parameters and prostate cancer aggressiveness parameters	—

Secondary

Measure	Time frame
Assess the effect of rosuvastatin addition to surgical castration in metastatic prostate cancer patients on the clinical outcome in terms of disease progression and overall survival	—

Countries

Egypt

Contacts

Public ContactRiham Karkeet

National Cancer Institute Cairo University

riham.karkeet@nci.cu.edu.eg01220112453

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026